Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients

Advances in Therapy

Volumn 24, Issue 2, 2007, Pages 387-393

  Sit, Dede ^a   Kadiroglu, Ali Kemal ^a   Kayabasi, Hasan ^a   Yilmaz, M Emin ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

CAPD; Mupirocin; Peritonitis; Staphylococcal nasal carriage

Indexed keywords

CEFAZOLIN; GENTAMICIN; PSEUDOMONIC ACID; TEICOPLANIN;

ADULT; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HUMAN; MALE; NOSE SMEAR; OINTMENT; PERITONITIS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MUPIROCIN; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; PROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS;

EID: 34250797358     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849908     Document Type: Article

References (14)

1. Turkish Society of Nephrology. Clinical Trial Registry. Istanbul, Turkey: Turkish Society of Nephrology; 2004.
2. Piraino B. Peritoneal infections. Adv Reu Replace Ther. 2000;7:280-288.
3. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol. 1996;7:2403-2408.
4. Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO J. 2000;46:S13-S17.
5. Kingwatanakul P, Warady BA. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis. Adv Perit Dial. 1997;13:281-284.
6. Sewell CM, Clarridge J, Lacke C, Weinman EJ, Young EJ. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA. 1982;248:1493-1495.
7. Wanten GJA, van Oost P, Schneeberger PM, Koolen MI. Nasal carriage and peritonitis by Staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study. Perit Dial Int. 1996;16:352-356.
8. Zimmerman SW, Ahrens E, Johnson CA, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis. 1991;18:225-231.
9. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial. 1992;9:242-245.
10. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996;27:695-700.
11. Mylotte JM, Kahler L, Jackson E. "Pulse" nasal mupirocin maintenance regimen in patients undergoing continuous ambulatory peritoneal dialysis. Infect Control Hosp Epidemiol. 1999; 20:741-745.
12. Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Adv Perit Dial. 2000;16:257-261.
13. Perez-Fontan M, Garcia-Falcon T, Rosales M, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis. 1993;22:708-712.
14. Cancho B, Garduno E, Dominguez C, Blanco J, Caravaca F. Long-term results of an eradication regime against Staphylococcus aureus in patients treated with peritoneal dialysis [in Spanish]. Nefrologia. 2001;21:464-470.